ArticleJournal of pharmacy & bioallied sciences2025
Clinicopathological Spectrum of Acute Myeloid Leukemia and Treatment Outcomes in Kashmiri Population: A Prospective Study.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and Aims: The prognosis for acute myeloid leukemia (AML) in adults is poor. The epidemiologic profile of patients varies substantially across geographic locales, as do the cytogenetic abnormalities and FAB subtype of AML. Kashmiris are a genetically conserved population. In this study, we are investigating clinical and laboratory factors and outcomes to establish treatment protocols. Methodology: This was a prospective study with clinical profiles and laboratory parameters of 100 case records. The primary objectives were to know the demographic profile of AML, prevalence of various FAB subtypes, cytogenetic abnormalities, and induction outcomes at our centre. Results: Median age was 50 years. The most common FAB subtype observed was AML M2. Pallor was observed in all patients as a clinical sign, while splenomegaly was noted in 41%, hepatomegaly in 23%, lymphadenopathy in 7%, and extramedullary disease in 6%. The ELN risk stratification for patients who have received 3 + 7 demonstrated a significant influence on complete remission rates ( Conclusions: Survival correlated significantly with risk stratification (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.